Captrust Financial Advisors Castle Biosciences Inc Transaction History
Captrust Financial Advisors
- $33 Billion
- Q3 2024
A detailed history of Captrust Financial Advisors transactions in Castle Biosciences Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 8,072 shares of CSTL stock, worth $238,204. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,072
Previous 21,125
61.79%
Holding current value
$238,204
Previous $459,000
49.89%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CSTL
# of Institutions
202Shares Held
26MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$89.9 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$53.9 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$51.6 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.54MShares$45.4 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$37.2 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $776M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...